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Abstract
Background: Computer simulation models can project long-term patient outcomes and inform health policy. We
internally validated and then calibrated a model of HIV disease in children before initiation of antiretroviral therapy to
provide a framework against which to compare the impact of pediatric HIV treatment strategies.
Methods: We developed a patient-level (Monte Carlo) model of HIV progression among untreated children <5 years
of  age,  using  the  Cost-Effectiveness  of  Preventing  AIDS  Complications  model  framework:  the  CEPAC-Pediatric
model.  We  populated  the  model  with  data  on  opportunistic  infection  and  mortality  risks  from  the  International
Epidemiologic Database to Evaluate AIDS (IeDEA), with mean CD4% at birth (42%) and mean CD4% decline (1.4%/
month)  from  the  Women  and  Infants’  Transmission  Study  (WITS).  We  internally  validated  the  model  by  varying
WITS-derived  CD4%  data,  comparing  the  corresponding  model-generated  survival  curves  to  empirical  survival
curves from IeDEA, and identifying best-fitting parameter sets as those with a root-mean square error (RMSE) <0.01.
We then calibrated the model to other African settings by systematically varying immunologic and HIV mortality-
related input parameters. Model-generated survival curves for children aged 0-60 months were compared, again
using RMSE, to UNAIDS data from >1,300 untreated, HIV-infected African children.
Results: In internal validation analyses, model-generated survival curves fit IeDEA data well; modeled and observed
survival at 16 months of age were 91.2% and 91.1%, respectively. RMSE varied widely with variations in CD4%
parameters; the best fitting parameter set (RMSE = 0.00423) resulted when CD4% was 45% at birth and declined by
6%/month (ages 0-3 months) and 0.3%/month (ages >3 months). In calibration analyses, increases in IeDEA-derived
mortality risks were necessary to fit UNAIDS survival data.
Conclusions: The CEPAC-Pediatric model performed well in internal validation analyses. Increases in modeled
mortality risks required to match UNAIDS data highlight the importance of pre-enrollment mortality in many pediatric
cohort studies.
Citation: Ciaranello AL, Morris BL, Walensky RP, Weinstein MC, Ayaya S, et al. (2013) Validation and Calibration of a Computer Simulation Model of
Pediatric HIV Infection. PLoS ONE 8(12): e83389. doi:10.1371/journal.pone.0083389
Editor: Ravi Jhaveri, University of North Carolina School of Medicine, United States of America
Received May 16, 2013; Accepted November 4, 2013; Published December 13, 2013
Copyright: © 2013 Ciaranello et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the National Institutes of Health (International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT);
National Institute of Allergy and Infectious Diseases, through K01 AI078754, K24 AI062476, R01 AI058736, R01 AI093269 (RPW), U01 AI069911,
U01AI09919 (IeDEA West Africa); the Harvard Center for AIDS Research); the Elizabeth Glaser Pediatric AIDS Foundation, the March of Dimes
Foundation, and the Massachusetts General Hospital Executive Committee on Research. Overall support for IMPAACT was provided by the National
Institute of Allergy and Infectious Diseases (NIAID) [U01 AI068632], the Eunice Kennedy Shriver National Institute of Child Health and Human
Development (NICHD), and the National Institute of Mental Health (NIMH) [AI068632]. The content is solely the responsibility of the authors and does not
necessarily represent the official views of the NIH. This work was supported by the Statistical and Data Analysis Center at Harvard School of Public Health,
under the National Institute of Allergy and Infectious Diseases cooperative agreement #5 U01 AI41110 with the Pediatric AIDS Clinical Trials Group
PLOS ONE | www.plosone.org 1 December 2013 | Volume 8 | Issue 12 | e83389(PACTG) and #1 U01 AI068616 with the IMPAACT Group. Support of the sites was provided by the National Institute of Allergy and Infectious Diseases
(NIAID) and the NICHD International and Domestic Pediatric and Maternal HIV Clinical Trials Network funded by NICHD (contract number N01-DK-9-001/
HHSN267200800001C). Sophie Desmonde is a fellow of the École des Hautes Etudes en Santé Publique (EHESP), Rennes, France. The funders had no
role in study design, data analysis, interpretation of results, or decision to publish.
Competing interests: The authors have declared that no competing interests exist.
* . E-mail: aciaranello@partners.org
Introduction
Key  clinical  and  operational  research  questions  related  to
prevention,  diagnosis,  and  therapy  for  HIV-infected  children
remain unanswered. For example, estimates of the long-term
outcomes  of  immediate  versus  deferred  ART  initiation
strategies for children 0-5 years of age, the cost-effectiveness
of alternative first-line ART regimens, and the relative value of
early infant diagnosis algorithms are needed to inform HIV care
guidelines [1–3].
While  clinical  trials  and  cohort  studies  will  continue  to
address  these  questions,  computer  simulation  models
comprise important adjuncts to these more traditional research
methods.  Models  can  integrate  available  data,  project  long-
term  clinical  and  economic  outcomes  beyond  study  periods,
identify  influential  parameters  for  which  additional  data  are
needed, and inform care and treatment guidelines [4–14]. To
date,  three  published  analyses  have  reported  on  simulation
models  of  HIV-infected  children:  a  Markov  model  used  to
evaluate  the  cost-effectiveness  of  cotrimoxazole  prophylaxis
and of laboratory monitoring of ART, and a decision-analytic
model of strategies for early infant diagnosis [15–17].
The  Cost-Effectiveness  of  Preventing  AIDS  Complications
(CEPAC) model is a validated, individual patient-level (Monte
Carlo)  simulation  of  HIV  disease  in  adults  that  has  informed
HIV  testing  and  treatment  policy  in  the  United  States  and
internationally [4,5,18–22]. Building on the adult CEPAC model
platform, we developed a simulation model of HIV disease in
infants  and  children  <5  years  of  age,  the  CEPAC-Pediatric
model,  to  address  policy  questions  related  to  prevention,
diagnosis and treatment of pediatric HIV. The objectives of this
analysis were to internally validate the structure of the CEPAC-
Pediatric  model;  to  calibrate  the  model  to  survival  data  from
untreated HIV-infected children in sub-Saharan Africa; and to
describe  this  work  in  an  open-access  forum  using
recommended reporting practices [23–25].
Methods
Ethics
This work was approved by the Partners Healthcare IRB.
Analytic overview
We  developed  a  microsimulation  model  of  pediatric  HIV
disease  progression,  the  CEPAC-Pediatric  model.  As  in  the
adult  CEPAC  model,  clinical  events  are  first  simulated  and
validated in the absence of ART (a "natural history" model), in
order to describe disease progression in the absence of ART
and  to  provide  a  framework  against  which  to  compare  the
impact  of  HIV  treatment  [4,5].  In  collaboration  with  the
International  Epidemiologic  Databases  to  Evaluate  AIDS
(IeDEA)  consortium  [26,27],  we  derived  model  input
parameters  for  the  CEPAC-Pediatric  model,  reflecting
outcomes in HIV-infected children prior to the initiation of ART.
These model input data included rates of WHO Stage 3 and
Stage 4 clinical events, tuberculosis (TB), and mortality [28],
stratified by age and CD4%.
Internal model validation is a formal methodology to assess
the  validity  of  model  structure.  In  internal  calibration,  the
empiric  data  values  used  in  the  modeling  analysis  ("model
inputs")  are  compared  to  model-generated  results  ("model
outputs"), in order to assess model performance for analyses
related  to  a  single  data  set  [19,24,25,29–31].  We  conducted
internal  model  validation  by  comparing  model-generated
results to the clinical event and mortality risks observed in the
same  IeDEA  cohort  that  contributed  model  input  data.  For
internal validation, selected immunologic parameters that were
not available from IeDEA were based on data from the Women
and Infants' Transmission Study (WITS) [32–34].
Model calibration is a methodology distinct from validation. In
model  calibration,  sometimes  referred  to  as  “model  fitting,”
investigators identify the values for key data parameters that
will  allow  model  projections  to  match  empiric  observations.
Calibration seeks to explicitly modify model input parameters,
in order to make the model useful for predicting outcomes in
cohorts or datasets distinct from the dataset used in internal
validation  [19,23–25,29].  The  IeDEA  East  African  cohort
represents  a  highly  selected  population  of  children  with
excellent  access  to  HIV  care.  In  order  to  produce  analyses
more generalizable to other African settings, we identified data
parameter sets that allowed model output to match published
survival  curves  from  a  pooled  UNAIDS  analysis  of  >1,300
untreated,  perinatally  HIV-infected  children  in  eight  sub-
Saharan African countries [30,35–38].
Model structure
The  CEPAC-Pediatric  model  is  a  first-order,  patient-level
Monte  Carlo  simulation  model  (Figure  1).  Infants  enter  the
natural history model at birth, and are assumed to have been
HIV-infected either in utero or during delivery (intrapartum). A
random number generator is used to draw from user-specified
distributions of maternal HIV status (CD4 ≤350/μL or >350/μL;
receiving  or  not  receiving  ART),  PMTCT  exposure;
breastfeeding or replacement feeding; and infant CD4% at birth
(percentage  of  total  lymphocytes  that  are  CD4+  cells).  We
modeled  CD4%  as  the  primary  immunologic  measure  for
children <5 years of age because absolute CD4 count declines
dramatically  with  age,  even  in  the  absence  of  HIV  infection,
and  CD4%  is  therefore  a  more  stable  marker  of  immune
function  as  children  age  [3].  In  the  absence  of  ART,  each
simulated  child's  CD4%  declines  monthly  at  a  user-specified
Computer Simulation Model of Pediatric HIV
PLOS ONE | www.plosone.org 2 December 2013 | Volume 8 | Issue 12 | e83389rate until they reach age five. Older children, adolescents, and
adults  can  be  simulated  in  dedicated  analyses  using  the
CEPAC adult model; in conjunction with the CEPAC-Pediatric
model,  this  permits  projections  over  the  lifetimes  of  HIV-
infected children [4–6].
Disease  progression  in  the  CEPAC-Pediatric  model  is
characterized  by  monthly  transitions  among  health  states,
including chronic HIV infection, acute clinical events, and death
(Figure 1). Transitions between these health states depend on
current age (0-2, 3-5, 6-8, 9-11, 12-17, 18-23, 24-35, 36-47,
and  48-59  months)  and  CD4%  (<15%,  15-24%,  and  ≥25%)
during each month of the simulation. Simulated patients face
monthly  risks  of  up  to  10  types  of  acute  "clinical  events,"
including  opportunistic  infections  and  other  HIV-related
illnesses. For this analysis, reflecting available IeDEA data, we
modeled  3  mutually  exclusive  categories  of  clinical  events:
WHO Stage 3 events (WHO 3, excluding pulmonary and lymph
node  tuberculosis  (TB)),  WHO  Stage  4  events  (WHO  4,
excluding extrapulmonary TB), and TB events (at any anatomic
site) [28].
The  CEPAC-Pediatric  model  simulates  three  types  of
mortality. First, children with no history of acute clinical event
face  a  monthly  risk  of  HIV-related  death  ("chronic  HIV
mortality"),  stratified  by  current  age  and  CD4%.  Second,
children who experience a clinical event face "acute mortality"
risks in the first 30 days post-event, stratified by current age.
After  this  30-day  "acute  mortality"  period,  children  return  to
“chronic  HIV  mortality,”  though  with  increased  monthly  risks
compared to age/CD4%-matched children without a history of
clinical events. Third, in addition to HIV-related mortality, the
model  includes  a  monthly  risk  of  "non-AIDS  death,"  derived
from UNAIDS age- and sex-adjusted, country-specific mortality
rates that exclude the impact of HIV [39].
For each simulated infant, the model tracks clinical events,
changes in CD4%, and the amount of time spent in each health
state. After an individual simulated patient has died, the next
infant  enters  the  model.  Large  cohorts  (often  1  million-10
million  patients)  are  simulated  in  order  to  generate  stable
model outcomes. Once the entire cohort has been simulated,
summary  statistics  are  tallied,  including  number  and  type  of
clinical events and the proportion alive each month. Additional
information  about  CEPAC-Pediatric  model  structure,  data
sources,  and  procedures  for  initiating  new  collaborative
projects  are  available  at  web2.research.partners.org/cepac/
model.html.
IeDEA East Africa natural history model input data
(Tables 1 and 2)
IeDEA  is  an  international  consortium  of  AIDS  care  and
treatment centers [26,27,40]. In previous work, we estimated
incidence rates of first clinical event (WHO3, WHO4 and TB),
acute mortality (<30 days after clinical event), and chronic HIV
mortality  among  untreated,  HIV-infected  children  at  seven
clinical  sites  in  the  IeDEA  East  Africa  region  [28].  Additional
details about the IeDEA East Africa sites, as well as methods
for derivation of model input parameters, have previously been
described [28,41].
Baseline  cohort  characteristics  and  clinical  event
risks.  In the IeDEA East African cohort, all children enrolled in
care prior to 12 months of age (median: 5 months); 52% were
female  [28].  We  translated  observed  IeDEA  event  rates  into
monthly  transition  probabilities  (risks),  stratified  by  age  and
CD4% (Table 1). In children <6 months old, clinical event risks
ranged  from  5.2-7.8%/month  for  WHO3,  1.6-3.5%/month  for
WHO4, and 0.5-1.1%/month for TB. For children ≥6 months of
age,  clinical  event  risks  ranged  from  3.3-11.6%/month  for
WHO3, 1.4-6.4%/month for WHO4, and 0.8-3.8%/month for TB
(Table  1).  Modeled  risks  of  subsequent  clinical  events  were
assumed to be equal to risks of first events, within each age
and CD4% stratum.
Figure 1.  CEPAC-Pediatric model structure.  A schematic of the Cost-Effectiveness of Preventing AIDS Complications (CEPAC)-
Pediatric natural history model (see Methods for details).
doi: 10.1371/journal.pone.0083389.g001
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events, monthly risks of chronic HIV mortality ranged by CD4%
from  0.3-0.4%.  For  children  with  a  clinical  event,  the  30-day
risk of acute mortality following a WHO3 or WHO4 event was
3.4%, and the risk following TB events was 2.8%. After the 30-
day period post-event, monthly risks of "chronic HIV mortality"
ranged  by  CD4%  from  0.4-2.4%.  Non-AIDS  death  risks
(reflecting age- and sex-adjusted mortality rates) were held at
zero for internal validation analyses, since all observed deaths
in  the  IeDEA  cohort  were  coded  as  HIV-related  and  thus
Table 1. Selected model input parameters in the CEPAC-
Pediatric  natural  history  model  for  internal  validation
analyses.
Data from the IeDEA East Africa
cohort [28] Value  
Monthly risk of clinical events (%)
a Infants <6m of age Children ≥6m of age
WHO Stage 3 event 5.2-7.8 3.3-11.6  
WHO Stage 4 event 1.6-3.5 1.4-6.4  
Tuberculosis event 0.5-1.1 0.8-3.8  
Risk of death within 30 days of clinical event (%)  
After WHO Stage 3 or 4 event 3.4  
After TB event 2.8  
Monthly risk of death in infants and children with no history of clinical
event (%)
 
CD4% < 15 0.4  
CD4% 15-24 0.4  
CD4% ≥ 25 0.3  
Monthly risk of death in infants and children with history of clinical
event (%, occurring >30 days post-event))
 
CD4% < 15 2.4  
CD4% 15-24 0.8  
CD4% ≥ 25 0.4  
Data from WITS [33]b Value
Range evaluated in internal
validation analyses
Initial CD4%
distribution at birth
(mean, SD)
42.0% (9.4%) 42.0% - 50.0% 
c
Monthly rate of CD4%
decline
1.4% 0.3% - 8.0% 
c
IeDEA: International Epidemiologic Databases for the Evaluation of AIDS; WHO:
World  Health  Organization;  TB:  tuberculosis;  WITS:  Women  and  Infants
Transmission Study.
a. WHO Stage 4, Stage 4, and TB events defined according to WHO classifications
for HIV disease staging in children [3].
b.  The  publicly  available  WITS  dataset  includes  193  perinatally  HIV-infected
children (positive HIV co-culture or PCR by 4-6 weeks of age), with a median of 5.2
months of follow-up prior to initiation of 3-drug ART (Interquartile Range (IQR):
2.1-12.1  months;  AZT  monotherapy  was  permitted  during  the  follow-up  period)
[33]. Of the 193 perinatally HIV-infected children included in the WITS dataset, 180
(93%) had at least one CD4% measurement before ART initiation, 152 (79%) had
at least two values, and 121 (63%) had at least three; the first recorded CD4% was
observed at a median age of 5.0 days (IQR: 1.0-29.0 days)
c. See derivation of ranges for sensitivity analyses in Methods.
doi: 10.1371/journal.pone.0083389.t001
Table 2. Selected model input parameters in the CEPAC-
Pediatric natural history model for calibration analyses.
Data from the IeDEA East
Africa cohort [28] Value
Range evaluated in
calibration analyses
Monthly risk of clinical events (%) 
a
Identical to data parameters used in internal validation
analyses, above
Not varied for
calibration analyses
Risk of death within 30 days of clinical event (%)
Range, 0.5-5 X
IeDEA risk
After WHO Stage 3 or 4 event 3.4 1.7-16.8
After TB event 2.8 1.4-13.9
Monthly risk of death in infants and children with no
history of clinical event (%)
Range, 0.2-20 X
IeDEA risk
CD4% < 15 0.4 0.08-8.3
CD4% 15-24 0.4 0.07-7.2
CD4% ≥ 25 0.3 0.06-6.2
Monthly risk of death in infants and children with
history of clinical event (%, occurring >30 days post-
event)
Range, 0.2-20 X
IeDEA risk
CD4% < 15 2.4 0.5-48.0
CD4% 15-24 0.8 0.2-16.7
CD4% ≥ 25 0.4 0.08-7.9
Data from WITS [33]b Value
Range evaluated in
calibration analyses
Initial CD4% distribution at birth
(mean, SD)
42.0% (9.4%) 42.0% - 50.0% 
c
Monthly rate of CD4% decline 1.4% 0.3% - 8.0% 
c
Data from UNAIDS [39] Value
Range evaluated in
calibration analyses
HIV-deleted mortality for Burkina Faso, Côte d'Ivoire,
Kenya, South Africa, Tanzania, and Uganda 
d
 (monthly
risks)
 
0-11 months 0.41-0.49%
Not varied for
calibration analyses
12-59 months 0.04-0.05%
Not varied for
calibration analyses
IeDEA: International Epidemiologic Databases for the Evaluation of AIDS; WHO:
World  Health  Organization;  TB:  tuberculosis;  WITS:  Women  and  Infants
Transmission Study.
a. WHO Stage 4, Stage 4, and TB events defined according to WHO classifications
for HIV disease staging in children [3].
b.  The  publicly  available  WITS  dataset  includes  193  perinatally  HIV-infected
children (positive HIV co-culture or PCR by 4-6 weeks of age), with a median of 5.2
months of follow-up prior to initiation of 3-drug ART (Interquartile Range (IQR):
2.1-12.1  months;  AZT  monotherapy  was  permitted  during  the  follow-up  period)
[33]. Of the 193 perinatally HIV-infected children included in the WITS dataset, 180
(93%) had at least one CD4% measurement before ART initiation, 152 (79%) had
at least two values, and 121 (63%) had at least three; the first recorded CD4% was
observed at a median age of 5.0 days (IQR: 1.0-29.0 days)
c. See derivation of ranges for sensitivity analyses in Methods.
d. UNAIDS HIV-deleted mortality rates from these eight countries were weighted
by the proportion of children from each country included in the UNAIDS pooled
analysis used as a calibration target [35,36].
doi: 10.1371/journal.pone.0083389.t002
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calibration  analyses,  "non-AIDS"  mortality  rates  were  from
UNAIDS  HIV-deleted  life  tables  for  the  eight  sub-Saharan
countries which were included in the study (Table 2) [35,36,39].
WITS natural history model input data (Tables 1 and 2)
Immunologic  data.    Because  IeDEA  lacked  adequate
longitudinal CD4 data, we derived CD4% at birth and rate of
monthly CD4% decline from the US-based WITS, a longitudinal
cohort  study  (1990-2006)  of  HIV-infected  women  and  their
infants during pregnancy and the post-partum period [32–34].
Using  a  mixed  effects  model  for  the  primary  analysis,  we
estimated a mean CD4% at birth of 42.0% (standard deviation,
9.4%),  and  a  monthly  CD4%  decline  of  1.4%/month  prior  to
ART initiation [42]. In a secondary analysis in which CD4% was
permitted to decline by different rates in months 0-2 and 3+ of
life, we estimated a mean CD4% of 50.0% at birth, monthly
decline  of  6.4%/month  for  months  0-2,  and  0.3%/month  in
months 3+. Due to high variability around the point estimate for
this latter variable, likely due to small numbers of CD4% data in
older  infants,  we  used  these  results  to  inform  the  ranges  of
CD4% parameters for sensitivity analyses, rather than for the
primary analysis.
Internal model validation: Comparison of model-
generated results to empiric data from the IeDEA East
African region
Population  and  follow-up  time.    For  internal  validation
analyses,  we  simulated  a  population  of  HIV-infected  infants
from birth (assuming intrauterine or intrapartum infection), with
clinical characteristics of patients in the IeDEA cohort. To most
closely match the observed IeDEA data, we evaluated model-
generated  results  for  children  from  5-16  months  of  age,
reflecting a median age at enrollment in the IeDEA cohort of 5
months and a median of 11 months follow-up [28].
Internal  validation:  survival  outcomes.    We  compared
model-generated  survival  curves  from  5  to  16  months  after
birth to Kaplan-Meier survival curves directly from the IeDEA
East  African  regional  data.  We  first  assessed  model  results
using base-case parameter estimates. We then performed two-
way sensitivity analyses in which we simultaneously varied the
two parameters from WITS (CD4% at birth and monthly CD4%
decline). First, CD4% at birth was varied in 1.0% increments
from 42% (the result in the primary WITS analysis) to 50% (the
result from the secondary WITS analysis). This range includes
the value of 47%, which was the mean percentage recorded in
the  first  1-2  days  of  life  in  a  study  in  Durban,  South  Africa
[43,44]. Second, the monthly rate of CD4% decline was varied
from  0.3%  (the  lowest  value  from  the  secondary  WITS
sensitivity analysis) to 8.0% (an average of published values in
the first three months of life [43–45]). To reflect observations
that CD4% may decline more rapidly in the first few months of
life [43,44], we permitted CD4% to decline at different rates for
"younger" and "older" infants. We defined "younger" and "older"
age groups using threshold values of 3, 6, or 12 months of age,
and examined all combinations of CD4% at birth and monthly
CD4% decline in which CD4% decline was faster in “younger”
compared to “older” children.
For each parameter set, we compared model-based survival
curves to the empiric IeDEA survival curves at each month of
the  simulation  using  root-mean-square  error  (RMSE)  [30].
RMSE was calculated as the square root of the average of the
squared  difference  between  observed  and  projected  survival
proportions at each month over the course of the simulation
(5-16 months). We defined the best-fitting survival curves as
those with a RMSE <0.01. This method was chosen because it
is intuitive, computationally feasible with complex models, and
appropriate  for  data  drawn  primarily  from  a  single  source
[23–25,30].
Internal  validation:  clinical  event  risks.    In  addition  to
examining  survival  results,  we  also  compared  the  model-
generated rates of clinical events to the observed rates in the
IeDEA cohort. Because model-based analyses do not rely on a
single convention for comparing model results to data [24,25],
we defined a good-fitting result as one where model-projected
incidence rates were within 10-15% (relative) of observed data,
based on previous work [5]. To reflect as closely as possible
the IeDEA clinical cohort, simulated infants entered the model
at birth, with the initial CD4% distribution and rates of monthly
CD4% decline identified in the best-fitting parameter set in the
internal  validation  survival  analyses  described  above.  Model-
based incidence rates for first clinical events between 5 and 16
months  of  age  were  projected  for  infants.  Number  of  events
and time at risk are not stratified by CD4% in the current model
output,  because  they  were  not  anticipated  for  use  in  future
policy analyses. To directly compare model output with IeDEA
data,  we  re-analyzed  IeDEA  event  rates  for  all  children
(combining all CD4% strata) at ages <6 and ≥6 months of age.
Model calibration: Comparison of model-generated
results to published pre-ART survival curves
Calibration  targets,  modeled  population,  and  follow-up
time.    Following  internal  validation  of  the  CEPAC-Pediatric
model, we compared model-generated results to survival data
reported  in  a  pooled  UNAIDS  analysis  of  perinatally  HIV-
infected children in sub-Saharan Africa [35–38]. In this UNAIDS
analysis, data were from 12 PMTCT studies in Burkina Faso,
Côte  d'Ivoire,  Kenya,  South  Africa,  Tanzania,  Uganda,
Zimbabwe and Botswana, reflecting >1,300 perinatally infected
infants (defined by a positive PCR test before 6 weeks of age).
Among  untreated  infants,  survival  was  estimated  by  Weibull
survival analysis to be 64% at 6 months, 49% at 12 months,
35% at 24 months, 25% at 36 months, 17% at 48 months, and
12%  at  60  months  [35–37].  To  compare  model-generated
results to these data, we used the CEPAC-Pediatric model to
simulate  a  cohort  of  infants  with  in  utero  or  intrapartum  HIV
infection from birth through 60 months of age.
Systematic  variation  in  model  input  parameters.    We
anticipated that there would be substantial differences in the
CD4%  at  birth,  rate  of  CD4%  decline,  and  mortality  risks
between  children  in  the  UNAIDS  and  IeDEA  East  Africa
cohorts.  To  calibrate  the  model  against  UNAIDS  data,  we
varied  all  CD4%  and  HIV-related  mortality  parameters,
individually and in combination, applying multipliers of 0.2 to 20
to the mortality risks observed in the IeDEA cohort (Tables 2
and 3). CD4% decline was modeled to be more rapid in the first
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analysis. Monthly risks for clinical events (WHO3, WHO4, and
TB) observed in the IeDEA cohort were similar to or greater
than  those  reported  in  the  literature  [45–50],  and  were
therefore not varied in calibration analyses. Non-AIDS mortality
rates  were  also  held  constant,  using  a  weighted  average  of
UNAIDS HIV-deleted mortality data for the eight countries in
the UNAIDS analysis (Table 2) [35,36,39].
Model-generated results were compared to empiric data in a
step-wise fashion based on six key time points after birth (6,
12,  24,  36,  48,  and  60  months).  We  first  identified  all
combinations  of  CD4%  values  and  mortality  risk  multipliers
(Table 3) that led to model-generated mortality within 1% of the
UNAIDS mortality estimate at 6 months of age (63-65%). For
each of those parameter sets, multipliers were next applied to
Table 3. Systematic variations in model input parameters
for calibration of CEPAC-Pediatric model.
Parameter Values
Initial CD4% (mean % for cohort, SD = 9%)
All Ages 42, 45, 47, 50
Monthly CD4% decline at each age (%) 
a
0-3 months 3.0, 4.0, 6.4 or 8.0
4-60 months 0.3, 0.5 or 1.4
Monthly risks of clinical events (%)
All ages Held equal to IeDEA clinical event risks
HIV-deleted mortality risk
(%)
 
All ages
Held equal to weighted average of HIV-deleted
mortality rates from countries represented in
UNAIDS cohort
Acute mortality risk (%) b
All Ages 0.5-5.0 X IeDEA risks (increments of 0.5)
Chronic HIV mortality risk c
0-6 months 1.0-20.0 X IeDEA risks (increments of 1.0)
7-12 months 1.0-20.0 X IeDEA risks (increments of 1.0)
13-24 months 0.5-5.0 X IeDEA risks (increments of 0.5)
25-36 months 0.5-5.0 X IeDEA risks (increments of 0.5)
37-48 months 0.2-2.0 X IeDEA risks (increments of 0.2)
49-60 months 0.2-2.0 X IeDEA risks (increments of 0.2)
IeDEA:  International  Epidemiologic  Database  to  Evaluate  AIDS,  East  African
region. m: month.
a. Values for monthly CD4% decline reflect more rapid decline in the first three
months of life than after age three months, based on published literature [43–45],
and the results of internal validation analyses.
b. Acute mortality risk: risk of death within 30 days of a clinical event (WHO Stage
3, WHO Stage 4, or tuberculosis; see Methods).
c. Chronic HIV mortality: monthly risk of death for patients with no history of a
clinical event, or for patients >30 days following a clinical event (see Methods). In
all evaluated parameter sets, multipliers for chronic HIV mortality were limited to
ranges  in  which  multipliers  applied  at  younger  ages  were  ≥  multipliers  at  older
ages.  Risks  were  therefore  permitted  to  remain  constant  or  decrease  (but  not
increase) with age. This leads to a total of 294,660 parameter combinations of
chronic HIV mortality multipliers, and 141.4 million total parameter sets examined
(see Methods).
doi: 10.1371/journal.pone.0083389.t003
chronic HIV mortality risks for ages 7-12 months. All parameter
sets  producing  model-generated  mortality  risks  within  1%
(absolute) of the target 12-month risk (48-50%) were retained
in the next step. Chronic HIV mortality risk multipliers were then
applied  to  ages  13-24  months;  parameter  sets  leading  to
results  within  1%  of  the  24-month  target  (34-36%)  were
retained. This process was repeated for time points of 36, 48,
and 60 months. In all evaluated parameter sets, multipliers for
chronic HIV mortality were limited to ranges in which multipliers
applied  at  younger  ages  were  greater  than  or  equal  to
multipliers  at  older  ages.  Risks  were  therefore  permitted  to
remain  constant  or  decrease  (but  not  increase)  with  age.
Finally, all parameter sets leading to model results within these
ranges were compared again to the UNAIDS mortality rates to
identify all parameters sets that resulted in a RMSE <0.01%.
Results
Internal model validation: Comparison of model-
generated results to empiric data from IeDEA
Internal validation of survival.  In simulations using IeDEA
clinical event risk data and WITS immunologic data ("IeDEA-
WITS  projections"),  model-projected  survival  (91.2%  at  16
months) was slightly greater than the survival observed in the
IeDEA  cohort  (91.1%  at  16  months)  (Figure  2,  orange  line).
The RMSE for this model-generated survival curve was 0.0103,
reflecting an average absolute difference of 1.03% from IeDEA
observed survival.
Systematic  variation  in  both  CD4%  at  birth  and  monthly
CD4% decline led to 3,888 evaluated parameter sets, in which
the RMSE between model-generated and IeDEA survival data
varied  widely  (range,  0.00423  to  0.0798).  Of  these,  191
parameter  sets  were  identified  as  best-fitting,  with  a  RMSE
<0.01.  In  general,  survival  was  overestimated  in  analyses  in
which CD4% at birth was high and monthly CD4% decline was
slow, and underestimated under the opposite conditions. The
parameter  set  with  the  lowest  RMSE  (RMSE  =  0.000423)
included  CD4%  at  birth  of  45.0%,  monthly  CD4%  decline  of
6.0% in infants <3 months and monthly CD4% decline of 0.3%
in children > 3 months (Figure 2, red line).
Internal validation of clinical event risks.  The model also
projected  rates  of  clinical  events  that  fit  IeDEA  data  well.
Incorporating CD4% decline rates from the best-fitting internal
validation parameter sets, as well as competing clinical event
and  mortality  risks  from  the  IeDEA  cohort,  model-generated
incidence  rates  were  within  2-12%  of  observed  IeDEA  rates
(Table 4, Figure 3).
Model calibration: Comparison of model-generated
results to published UNAIDS pre-ART survival curves
We  examined  141  million  parameter  sets  (all  possible
combinations  from  Table  3).  We  identified  9,943  best-fitting
parameter  sets  through  the  step-wise  selection  process,  in
which  we  retained  only  parameter  sets  that  led  to  model-
generated mortality risks within ±1% of UNAIDS survival risks
at key time points (RMSE <0.01). Projected survival for the 10
best-fitting parameter sets with the lowest RMSE is shown in
Figure 4: UNAIDS survival and is depicted as the black line and
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the  UNAIDS  survival  curve.  Figure  4  also  shows  projections
using the IeDEA survival from the internal validation analyses,
to illustrate the lower mortality seen in the IeDEA cohort (green
line),  as  well  as  the  highest-  and  lowest-mortality  risk
parameter sets from Table 3 (red and blue lines) to show the
range that the model is capable of generating.
The individual components of 10 of the best-fitting parameter
sets  with  the  lowest  RMSE  are  shown  in  Table  5.  The  data
parameters  requiring  the  largest  increase  in  risk  to  match
UNAIDS survival data were acute mortality within 30 days of a
clinical event (multipliers applied to IeDEA event risks ranged
from 4-5 in all parameter sets), and chronic HIV mortality in the
first 12 months of life (multipliers of 14-17 for infants ages 0-6
months,  and  4-8  for  ages  7-12  months).  After  48  months  of
age, calibrated chronic HIV mortality risks were slightly lower
than IeDEA data (multipliers of 0.4-0.8).
Discussion
We developed a patient-level computer simulation model of
disease progression among perinatally HIV-infected infants --
the  CEPAC-Pediatric  model.  This  represents  the  first
description  of  a  Monte  Carlo  microsimulation  model  of
untreated  HIV  disease  in  children,  and  the  most  detailed
description  to  date  of  internal  validation  and  calibration  of  a
model  of  pediatric  HIV  disease  according  to  recommended
practices [15–17].
In  internal  validation  analyses,  using  a  single  set  of  input
parameters to assess model structure, model outputs closely
matched  empiric  data  from  the  IeDEA  East  African  regional
pediatric  cohort.  Model-projected  survival  was  closest  to
empiric survival data if the immunologic data parameters (not
available from IeDEA) included an average CD4% at birth of
45%, a CD4% decline of 6%/month for infants < 3 months of
age,  and  a  CD4%  decline  of  0.3%/month  for  children  >3
months of age. When model-projected clinical event risks were
compared to empiric IeDEA event risks, model results matched
observed data reasonably well. The difference between model-
generated results and observed data ranged from 2-12%, less
than the 10-15% criterion accepted as "good-fitting" in a prior
study [5].
In calibration analyses, we identified new values for model
input parameters that allowed our projections to match more
generalizable  survival  data  from  untreated,  African  children.
Large  increases  in  IeDEA-observed  mortality  risks  were
required in the first 12 months of life for model projections to
match UNAIDS survival data [35–38]. There are likely to be at
Figure 2.  Internal validation of survival outcomes: Observed survival curves from the IeDEA East African region and
projected results from the CEPAC-Pediatric Model.  The solid black stepped line represents observed survival in the IeDEA
cohort based on Kaplan-Meier analysis, beginning at 5 months of age. Dashed black lines reflect the upper and lower bounds of the
95% confidence intervals for IeDEA-observed survival. The orange line shows CEPAC model-projected survival using the "IeDEA-
WITS projection" data (RMSE = 0.0103). The best-fitting curve is shown with the red line, reflecting mean CD4% at birth of 45.0%,
CD4% decline of 6.0%/month in infants <3 months of age, and 0.3%/month for children >3 months of age (RMSE = 0.00423).
doi: 10.1371/journal.pone.0083389.g002
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analysis  were  collected  before  widespread  pediatric  ART
availability  (in  only  one  included  study  did  any  HIV-infected
children initiate ART) [36]. In contrast, children in IeDEA were
likely  to  initiate  ART  when  needed;  although  they  were  then
censored from our analysis, this likely averted many of the risks
of opportunistic infection and death that would have occurred
had no ART been available.
Second,  the  IeDEA  dataset  may  reflect  some  degree  of
“survivor bias:” children who survive the first months and years
of  life  may  be  longer-term  survivors,  with  slower  disease
progression  than  those  who  become  ill  in  infancy  and  are
unavailable  to  enroll  in  many  cohort  studies.  Infants  in  the
UNAIDS  analysis  were  followed  from  birth,  permitting  early
infant mortality to be observed and avoiding this survivor bias,
whereas infants in the IeDEA cohort enrolled at a median of 5
months of age. Our finding that IeDEA-observed mortality risks
in the first 12 months of life required the largest increases to
match UNAIDS data suggests that unobserved pre-enrollment
Table 4. Comparison of clinical event risks observed in the
IeDEA East Africa cohort and.
  Rates/100PY Monthly risk (%)  
Clinical event
and age
Model
generated
Observed
in IeDEAb
Model
generated
Observed
in IeDEAb
Difference in
rates (as %
of IeDEA
rate) 
c
WHO Stage 3          
<6m 66.16 67.53 5.36 5.47 2.0
≥6m 61.54 67.89 5.00 5.50 9.4
WHO Stage 4          
<6m 19.85 21.41 1.64 1.77 7.3
≥6m 28.92 32.83 2.41 2.70 11.9
Tuberculosis          
<6m 7.34 8.23 0.61 0.68 10.8
≥6m 15.88 17.93 1.32 1.48 11.5
PY: person-years; m: months
a. As described in the Methods, patients enter the model with CD4% at birth from
the best-fitting parameter set in the internal validation survival analyses (45.0%).
CD4% values decline as per the best-fitting parameter set (6.0%/month ages 0-3
months, 0.3%/month ages >3 months). Simulated infants face competing risks of
all  three  types  of  clinical  events,  as  well  as  "acute  mortality"  and  "chronic  HIV
mortality.”
b.  Due  to  differing  methods  of  reporting,  IeDEA  event  risks  (reported  for  three
distinct CD4 strata) could not directly be compared to model-projected event risks
(reported as a cohort average, where the cohort consists of a population with a
unique distribution of CD4% each month). To generate a comparable IeDEA risk
for each clinical event, we calculated an average of the three reported risks from
IeDEA (CD4 <15%, CD4 15-25%, CD4 >25%) weighted by the proportion of the
cohort in each CD4% strata during each month of the simulation.
c. Model-generated rates are expected to be slightly lower than IeDEA-observed
rates, due to:
1)  Model  accounting  of  clinical  events  (which  permits  only  one  event  to  be
recorded each month), and 2) competing risks of other events and “chronic HIV
mortality” in the model.
doi: 10.1371/journal.pone.0083389.t004
mortality was likely a key explanation for the overall very low
mortality observed in IeDEA. Such survivor bias has also been
described  in  other  cohorts  of  HIV-infected  children,  in  which
median age at enrollment is >1 year, and often up to 5 years
[47,51–55]. In studies that have enrolled children at younger
ages,  mortality  is  reported  to  be  two-  to  eight-fold  greater
among infants <12 months of age compared to older children
[46,47,53,56].  Consistent  with  this  literature,  several  good-
fitting  parameter  sets  in  our  model  calibration  analyses
required chronic HIV mortality risks after 48 months of age to
be reduced below the risks observed in the IeDEA cohort to
match  UNAIDS  data.  This  suggests  that  mortality  risks  for
children who have survived to age 4 may be less than the risks
among younger children in the IeDEA cohort. Empiric data on
CD4% stratified risks of acute clinical events and mortality for
untreated, HIV-infected children ages 2-5 years are limited; in
their absence, model-calibrated mortality estimates can inform
the impact of deferred ART initiation in children of these ages.
This analysis has several limitations. First, data to completely
parameterize the model were not available from IeDEA, and
immunologic data from the US-based WITS cohort were used
where IeDEA data were unavailable [33]. Due to the lack of an
independent source of data, we were unable to perform a true
validation of the model, and instead first performed an internal
validation of IeDEA OI and mortality risks and then separately
calibrated  the  model  to  fit  the  UNAIDS  survival  curves.
However,  the  flexibility  to  incorporate  data  from  a  variety  of
sources  and  to  evaluate  the  impact  of  these  heterogeneous
data sources is also a strength of modeling analyses [13]. The
WITS-derived  CD4%  inputs  were  varied  extensively  in
sensitivity  analyses,  and  found  to  have  modest  impact  on
goodness-of-fit  between  model-generated  and  observed
survival risks.
Second,  there  is  no  single  accepted  criterion  by  which  to
compare  model-generated  results  to  empiric  data.  Instead,
expert  guidance  recommends  that  investigators  choose  and
explicitly describe a criterion that fits their model structure and
data  sources  [5,23–25,30,57].  We  chose  RMSE  to  assess
goodness-of-fit between projected and observed survival. The
complex  microsimulation  structure  of  the  CEPAC  model
renders  Bayesian  analysis  computationally  infeasible  [58],
empiric datasets were too small to permit separate analyses in
training and validation sets. We therefore selected a method
that  is  transparent,  well-described  in  policy  models,  and
comparable  to  methods  used  to  validate  the  adult  CEPAC
model  [19].  Although  some  possible  parameter  sets  were
necessarily  excluded  with  this  approach,  we  sampled  the
parameter space systematically, varying all model parameters
in  small  increments  through  clinically  plausible  ranges  and
considering all 141 million resulting parameter combinations.
In summary, we report the development, internal validation,
and calibration of the CEPAC-Pediatric natural history model of
HIV  disease  progression  in  young  children.  The  model
demonstrates  excellent  performance  in  internal  validation
analyses to evaluate model structure. The model also permits
wide-ranging sensitivity analyses on all key input parameters,
and variations in key clinical and immunologic parameters lead
to  model-generated  survival  curves  that  calibrate  closely  to
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children. Differences in the mortality risk parameters required
to match data from the IeDEA cohort (model internal validation)
and  the  UNAIDS  cohort  (model  calibration)  highlight  the
importance of early infant mortality before enrollment in many
cohort studies, as well as the ability of simulation models to
estimate mortality risks among children ages two to five in the
absence of such empiric data. This validated CEPAC-Pediatric
model will be well-suited to address critical policy questions in
pediatric HIV care for children from birth through five years of
age.
Figure  3.    Internal  validation  of  clinical  event  risk  outcomes:  CEPAC-Pediatric  model  results  compared  to  IeDEA
data.  Risks of clinical events from 5-16 months of age, as observed among infants in the IeDEA East Africa region and projected by
the CEPAC-Pediatric model. Simulated infants enter the model with the CD4% at birth identified in the best-fitting parameter set for
the internal validation survival analyses (45.0%), and CD4% values decline as per the best-fitting parameter set (6.0%/month ages
0-3 months, 0.3%/month ages ≥3 months). Simulated infants face competing risks of all three types of clinical events, as well as
"acute" and "chronic" mortality. Due to differing methods of reporting, IeDEA event risks (reported for three distinct CD4 strata) could
not directly be compared to model-projected event risks (reported as a cohort average, where the cohort consists of a population
with a unique distribution of CD4% each month). To generate a comparable IeDEA risk for each clinical event, we calculated an
average of the three reported risks from IeDEA (CD4 <15%, CD4 15-25%, CD4 >25%) weighted by the proportion of the cohort in
each CD4% strata during each month of the simulation. Model-generated rates are expected to be slightly lower than IeDEA-
observed rates, due to 1) model accounting of OIs (which permits only one OI to be recorded each month), and 2) competing risks
of other OIs and chronic HIV mortality in the model.
TB: tuberculosis, PY: person-years.
doi: 10.1371/journal.pone.0083389.g003
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PLOS ONE | www.plosone.org 9 December 2013 | Volume 8 | Issue 12 | e83389Figure 4.  CEPAC-Pediatric model calibration analyses: Projected survival (A).  Model-projected survival curves from age 0-60
months for: 1) Base-case IeDEA mortality data used in the internal validation analyses (purple line); 2) the empiric UNAIDS mortality
data (black line); 3) 10 of the best-fitting parameter sets (with the lowest RMSE) identified in the calibration analyses (group of
colored lines surrounding and almost completely overlapping with the black UNAIDS line); 4) the lowest-mortality risk parameter set
from Table 3 (blue line) and 5) the highest-mortality risk parameter set from Table 3 (red line). The 10 sample best-fitting parameter
sets from calibration analyses are almost entirely obscured by the UNAIDS survival data (black line) due to their extremely close fit
to the calibration target. The IeDEA survival curve from internal validation analyses, and both the highest- and lowest-mortality risk
parameter sets are all projected to 60 months of age for comparison only, as they did not meet the threshold of UNAIDS risk ±1% at
6 months and therefore were not formally evaluated at subsequent time points in the calibration analyses.
B: A zoom plot, enlarging the results for months 0-6, shows the nearly-overlapping curves in larger detail.
doi: 10.1371/journal.pone.0083389.g004
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survival data.
      Chronic HIV mortality multiplier c  
Mean CD4% at birthMonthly CD4% decline aAcute clinical event mortality multiplier b0-6m7-12m13-24m25-36m37-48m49-60mRoot-mean-squared error (RMSE) d
10 best-fitting parameter sets
45 4, 0.5 4 17 7 3 1.5 1.2 0.4 0.00122
42 3, 0.5 4 17 7 3 1.5 1.2 0.4 0.00146
50 4, 0.5 5 17 8 3.5 2 1.6 0.4 0.00152
47 3, 0.5 5 17 8 3.5 2 1.6 0.4 0.00162
50 4, 0.5 5 17 8 3.5 2 1.6 0.6 0.00172
50 4, 0.5 5 17 8 3.5 2 1.8 0.4 0.00173
47 8, 0.3 4 14 4 1.5 1 1 0.6 0.00174
45 6.4, 0.3 4 15 5 2 1.5 1.4 0.6 0.00176
47 3, 0.5 5 17 8 3.5 2 1.6 0.6 0.00176
45 6.4, 0.3 4 15 5 2 1.5 1.4 0.8 0.00181
Base-case IeDEA survival from internal validation analysis, projected to 60 months of age
45 6, 0.3 1 1 1 1 1 1 1 0.383
Lowest-mortality risk parameter set from Table 3, projected to 60 months of age
50 3, 0.3 0.5 1 1 0.5 0.5 0.2 0.2 0.575
Highest-mortality risk parameter set from Table 3, projected to 60 months of age
42 8, 1.4 5 20 20 5 5 2 2 0.236
a. CD4% decline is shown as monthly decline (in CD4 percentage points) for months 1-3 of life, followed by for months 4+ of life.
b. Multipliers were applied to the monthly risks of "acute mortality" derived from the IeDEA cohort (defined as mortality <30 days following a WHO3, WHO4, or TB clinical
event).
c. Multipliers were applied to monthly risks of "chronic HIV mortality" derived from the IeDEA cohort (defined separately as mortality risks among infants with no history of
clinical event, or >30 days after a clinical event for infants with a history of clinical event).
d. Root-mean-squared error of CEPAC-Pediatric model projections compared to UNAIDS survival data at 6, 12, 24, 36, 48, and 60 months of age. RMSE is calculated by 1)
calculating the difference between observed and projected survival proportions at each time point, 2) squaring these six absolute differences, 3) averaging the squared
values, and 4) taking the square root of this average value. RMSE reflects an average difference between observed and projected survival (as a percent) over the six time
points.
doi: 10.1371/journal.pone.0083389.t005
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